Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.
Código da empresaKARD
Nome da EmpresaKardigan Inc
Data de listagemJun 18, 2026
CEOGianakakos (Tassos Anastasios)
Número de funcionários420
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 18
Endereço506 Carnegie Center Drive, Suite 201
CidadePRINCETON JUNCTION
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal08540
Telefone14155733220
Sitehttp://www.kardigan.bio
Código da empresaKARD
Data de listagemJun 18, 2026
CEOGianakakos (Tassos Anastasios)